We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Serum Insulin-Like Growth Factor-1 Predicts Disease Progression and Survival in Patients with Hepatocellular Carcinoma Who Undergo Transarterial Chemoembolization.
- Authors
Cho, EunJu; Kim, Hyo-Cheol; Lee, Jeong-Hoon; Jeong-ju Yoo; Choi, Won-Mook; Cho, Young Youn; Lee, Min Jong; Cho, Yuri; Lee, Dong Hyeon; Lee, Yun Bin; Yu, Su Jong; Kim, Yoon Jun; Yoon, Jung-Hwan; Chung, Jin Wook; Kim, Chung Yong; Lee, Hyo-Suk
- Abstract
Insulin like-growth factor-1 (IGF-1) reflects hepatic synthetic function and plays a major role in the development and progression of various cancers. In the present study, we investigated whether baseline serum IGF-1 levels predict time-to-progression (TTP) and overall survival (OS) in hepatocellular carcinoma (HCC) patients treated with transarterial chemoembolization (TACE). A total of 155 consecutive treatment-naive patients with HCC who had undergone TACE as initial treatment were included from a prospective cohort. Baseline serum IGF-1 levels were analyzed with regard to their associations with disease progression and survival. During a median follow-up period of 41.8 months, patients with low IGF-1 levels showed significantly shorter TTP (median, 6.0 months; 95% confidence interval [CI], 4.5–7.6) than patients with high IGF-1 levels (median, 16.5 months; 95% CI, 4.9–28.1; p = 0.003). In the multivariate analysis, BCLC stage, serum vascular endothelial growth factorlevels, and IGF-1 levels were independent risk factors for disease progression. The hazard ratio (HR) of progression for each 10 ng/mL decrease in IGF-1 level was 1.072 (95% CI, 1.029–1.117; p = 0.001). Furthermore, together with tumor size, stage, and treatment response, IGF-1 levels were an independent predictor of poorer survival (for each 10 ng/mL decrease in IGF-1 level; HR, 1.057; 95% CI, 1.001–1.115; p = 0.045). In conclusion, low baseline IGF-1 levels independently correlated with shorter TTP and poorer OS in patients with HCC who underwent TACE.
- Subjects
SOMATOMEDIN C; DISEASE progression; LIVER cancer patients; FOLLOW-up studies (Medicine); LIVER cancer; CONFIDENCE intervals; EPIDEMIOLOGY
- Publication
PLoS ONE, 2014, Vol 9, Issue 3, p1
- ISSN
1932-6203
- Publication type
Article
- DOI
10.1371/journal.pone.0090862